FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209134412> ?p ?o ?g. }

• W3209134412 endingPage "S135" @default.
• W3209134412 startingPage "S134" @default.
• W3209134412 abstract "Purpose/Objective(s)Low dose rate (LDR) brachytherapy alone or with external beam radiation (EBRT) results in excellent rates of biochemical control in patients (pts) with prostate cancer (PCa). Understanding failure patterns in pts with biochemical recurrence (BCR) may inform implant technique or pt selection. The primary objective of this study was to describe locations of recurrence on multiparametric MRI (mpMRI) and prostate specific membrane antigen (PSMA) imaging in pts with BCR after LDR brachytherapy.Materials/MethodsPts with BCR after definitive LDR (± EBRT, ± androgen deprivation therapy (ADT)) referred for IRB approved imaging protocols were included. All pts underwent 3T mpMRI (T2 weighted, dynamic contrast-enhanced, and diffusion-weighted imaging) prospectively reviewed by prostate-dedicated radiologists. A subset of pts underwent PSMA-PET/CT imaging. Pathologic confirmation was obtained unless contraindicated. Prostate lesions were categorized as left (L)/right (R)/midline (ML); transitional zone (TZ)/peripheral zone (PZ); apical/mid/base; and anterior/posterior/central. Locations of recurrence (prostate, seminal vesicles (SV), lymph nodes (LN) and distant metastases (DM)) were recorded and reported descriptively.ResultsBetween Jan 2011 and Feb 2021, 57 pts with BCR after LDR underwent prostate mpMRI. Treatment was LDR (n = 39) or EBRT + LDR (n = 18), ± ADT (n = 12). At time of LDR, initial Gleason score was ≤6 (n = 29), 7 (n = 19), 8-9 (n = 8), unknown (n = 1) and median PSA was 6 ng/mL (3.4-49). Of dosimetry available (n = 27), 2 had D90 < 90%. Median time from LDR to mpMRI was 6.7 yrs (0.8-18.3). At time of mpMRI, median pt age was 68 yrs (51-85), median PSA was 5.64 ng/mL (0.17-37.47). Lesions (n = 67) in the prostate/SV were detected in 45/57 pts on mpMRI, with a median lesion size of 1.2 cm (0.3-3.6). SV involvement was present in 20/45 patients with mpMRI detected lesions. Locations of mpMRI prostate lesions were L (n = 19) vs R (n = 16) vs ML (n = 15); TZ (n = 22) vs PZ (n = 14); apical (n = 17) vs mid (n = 25) vs base (n = 23); and anterior (n = 13) vs posterior (n = 0) vs central (n = 8). In pts with PSMA (n = 32), 31 had uptake in the prostate (n = 16, 14 detected on mpMRI) and SV (n = 12, 10 detected on mpMRI). One pt had uptake in the prostate+SV detected only on PSMA. Extraprostatic uptake on PSMA included LN (n = 15), DM (n = 5) and penile bulb (n = 1). Of 37 pts who had prostate/SV biopsy, tumor recurrence was confirmed in 31 (prostate (n = 25) and SV (n = 12)). Three of 6 pts with negative biopsy had no lesion on mpMRI. SV recurrence (imaging ± biopsy) occurred in 18/39 pts with LDR alone and in 5/18 with LDR + EBRT.ConclusionIn this cohort of pts with BCR following LDR, the predominant locations of local recurrence were in the anterior/central TZ and SV. PSMA corroborated the majority of mpMRI findings and often demonstrated LN and DM. These findings may inform LDR technique and impact patient selection or pre-treatment imaging evaluation; and should be confirmed in larger subsets and correlated with post-implant dosimetry. Low dose rate (LDR) brachytherapy alone or with external beam radiation (EBRT) results in excellent rates of biochemical control in patients (pts) with prostate cancer (PCa). Understanding failure patterns in pts with biochemical recurrence (BCR) may inform implant technique or pt selection. The primary objective of this study was to describe locations of recurrence on multiparametric MRI (mpMRI) and prostate specific membrane antigen (PSMA) imaging in pts with BCR after LDR brachytherapy. Pts with BCR after definitive LDR (± EBRT, ± androgen deprivation therapy (ADT)) referred for IRB approved imaging protocols were included. All pts underwent 3T mpMRI (T2 weighted, dynamic contrast-enhanced, and diffusion-weighted imaging) prospectively reviewed by prostate-dedicated radiologists. A subset of pts underwent PSMA-PET/CT imaging. Pathologic confirmation was obtained unless contraindicated. Prostate lesions were categorized as left (L)/right (R)/midline (ML); transitional zone (TZ)/peripheral zone (PZ); apical/mid/base; and anterior/posterior/central. Locations of recurrence (prostate, seminal vesicles (SV), lymph nodes (LN) and distant metastases (DM)) were recorded and reported descriptively. Between Jan 2011 and Feb 2021, 57 pts with BCR after LDR underwent prostate mpMRI. Treatment was LDR (n = 39) or EBRT + LDR (n = 18), ± ADT (n = 12). At time of LDR, initial Gleason score was ≤6 (n = 29), 7 (n = 19), 8-9 (n = 8), unknown (n = 1) and median PSA was 6 ng/mL (3.4-49). Of dosimetry available (n = 27), 2 had D90 < 90%. Median time from LDR to mpMRI was 6.7 yrs (0.8-18.3). At time of mpMRI, median pt age was 68 yrs (51-85), median PSA was 5.64 ng/mL (0.17-37.47). Lesions (n = 67) in the prostate/SV were detected in 45/57 pts on mpMRI, with a median lesion size of 1.2 cm (0.3-3.6). SV involvement was present in 20/45 patients with mpMRI detected lesions. Locations of mpMRI prostate lesions were L (n = 19) vs R (n = 16) vs ML (n = 15); TZ (n = 22) vs PZ (n = 14); apical (n = 17) vs mid (n = 25) vs base (n = 23); and anterior (n = 13) vs posterior (n = 0) vs central (n = 8). In pts with PSMA (n = 32), 31 had uptake in the prostate (n = 16, 14 detected on mpMRI) and SV (n = 12, 10 detected on mpMRI). One pt had uptake in the prostate+SV detected only on PSMA. Extraprostatic uptake on PSMA included LN (n = 15), DM (n = 5) and penile bulb (n = 1). Of 37 pts who had prostate/SV biopsy, tumor recurrence was confirmed in 31 (prostate (n = 25) and SV (n = 12)). Three of 6 pts with negative biopsy had no lesion on mpMRI. SV recurrence (imaging ± biopsy) occurred in 18/39 pts with LDR alone and in 5/18 with LDR + EBRT. In this cohort of pts with BCR following LDR, the predominant locations of local recurrence were in the anterior/central TZ and SV. PSMA corroborated the majority of mpMRI findings and often demonstrated LN and DM. These findings may inform LDR technique and impact patient selection or pre-treatment imaging evaluation; and should be confirmed in larger subsets and correlated with post-implant dosimetry." @default.
• W3209134412 created "2021-11-08" @default.
• W3209134412 creator A5010459302 @default.
• W3209134412 creator A5022455023 @default.
• W3209134412 creator A5025234044 @default.
• W3209134412 creator A5026470145 @default.
• W3209134412 creator A5038850729 @default.
• W3209134412 creator A5038941750 @default.
• W3209134412 creator A5045705952 @default.
• W3209134412 creator A5063392701 @default.
• W3209134412 creator A5067251812 @default.
• W3209134412 creator A5076213753 @default.
• W3209134412 creator A5081575792 @default.
• W3209134412 creator A5081833588 @default.
• W3209134412 creator A5082080836 @default.
• W3209134412 date "2021-11-01" @default.
• W3209134412 modified "2023-09-27" @default.
• W3209134412 title "Detection of Failure Patterns Using Advanced Imaging in Patients With Biochemical Recurrence Following Low Dose Rate Brachytherapy for Prostate Cancer" @default.
• W3209134412 doi "https://doi.org/10.1016/j.ijrobp.2021.07.304" @default.
• W3209134412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700466" @default.
• W3209134412 hasPublicationYear "2021" @default.
• W3209134412 type Work @default.
• W3209134412 sameAs 3209134412 @default.
• W3209134412 citedByCount "0" @default.
• W3209134412 crossrefType "journal-article" @default.
• W3209134412 hasAuthorship W3209134412A5010459302 @default.
• W3209134412 hasAuthorship W3209134412A5022455023 @default.
• W3209134412 hasAuthorship W3209134412A5025234044 @default.
• W3209134412 hasAuthorship W3209134412A5026470145 @default.
• W3209134412 hasAuthorship W3209134412A5038850729 @default.
• W3209134412 hasAuthorship W3209134412A5038941750 @default.
• W3209134412 hasAuthorship W3209134412A5045705952 @default.
• W3209134412 hasAuthorship W3209134412A5063392701 @default.
• W3209134412 hasAuthorship W3209134412A5067251812 @default.
• W3209134412 hasAuthorship W3209134412A5076213753 @default.
• W3209134412 hasAuthorship W3209134412A5081575792 @default.
• W3209134412 hasAuthorship W3209134412A5081833588 @default.
• W3209134412 hasAuthorship W3209134412A5082080836 @default.
• W3209134412 hasBestOaLocation W32091344121 @default.
• W3209134412 hasConcept C121608353 @default.
• W3209134412 hasConcept C126322002 @default.
• W3209134412 hasConcept C126838900 @default.
• W3209134412 hasConcept C126894567 @default.
• W3209134412 hasConcept C143998085 @default.
• W3209134412 hasConcept C2776235491 @default.
• W3209134412 hasConcept C2777008409 @default.
• W3209134412 hasConcept C2777416452 @default.
• W3209134412 hasConcept C2779466945 @default.
• W3209134412 hasConcept C2780192828 @default.
• W3209134412 hasConcept C2989005 @default.
• W3209134412 hasConcept C509974204 @default.
• W3209134412 hasConcept C71924100 @default.
• W3209134412 hasConceptScore W3209134412C121608353 @default.
• W3209134412 hasConceptScore W3209134412C126322002 @default.
• W3209134412 hasConceptScore W3209134412C126838900 @default.
• W3209134412 hasConceptScore W3209134412C126894567 @default.
• W3209134412 hasConceptScore W3209134412C143998085 @default.
• W3209134412 hasConceptScore W3209134412C2776235491 @default.
• W3209134412 hasConceptScore W3209134412C2777008409 @default.
• W3209134412 hasConceptScore W3209134412C2777416452 @default.
• W3209134412 hasConceptScore W3209134412C2779466945 @default.
• W3209134412 hasConceptScore W3209134412C2780192828 @default.
• W3209134412 hasConceptScore W3209134412C2989005 @default.
• W3209134412 hasConceptScore W3209134412C509974204 @default.
• W3209134412 hasConceptScore W3209134412C71924100 @default.
• W3209134412 hasIssue "3" @default.
• W3209134412 hasLocation W32091344121 @default.
• W3209134412 hasLocation W32091344122 @default.
• W3209134412 hasOpenAccess W3209134412 @default.
• W3209134412 hasPrimaryLocation W32091344121 @default.
• W3209134412 hasRelatedWork W1952411274 @default.
• W3209134412 hasRelatedWork W1979955543 @default.
• W3209134412 hasRelatedWork W2010020620 @default.
• W3209134412 hasRelatedWork W2023503398 @default.
• W3209134412 hasRelatedWork W2071233319 @default.
• W3209134412 hasRelatedWork W2085529113 @default.
• W3209134412 hasRelatedWork W2165532162 @default.
• W3209134412 hasRelatedWork W2534674868 @default.
• W3209134412 hasRelatedWork W4243514755 @default.
• W3209134412 hasRelatedWork W4310112889 @default.
• W3209134412 hasVolume "111" @default.
• W3209134412 isParatext "false" @default.
• W3209134412 isRetracted "false" @default.
• W3209134412 magId "3209134412" @default.
• W3209134412 workType "article" @default.